These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2886245)

  • 21. Continuous intravenous infusions of famotidine maintain high intragastric pH in duodenal ulcer.
    Merki HS; Witzel L; Kaufman D; Kempf M; Neumann J; Röhmel J; Walt RP
    Gut; 1988 Apr; 29(4):453-7. PubMed ID: 3286384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Famotidine, a new H2-receptor antagonist. Effect on parietal, nonparietal, and pepsin secretion in man.
    Smith JL; Gamal MA; Chremos AN; Graham DY
    Dig Dis Sci; 1985 Apr; 30(4):308-12. PubMed ID: 2858363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamics of famotidine in humans.
    Chremos AN
    Am J Med; 1986 Oct; 81(4B):3-7. PubMed ID: 2877572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of 75 mg HOE 760, a novel H2-receptor antagonist, on daytime peptone-stimulated and nocturnal gastric acid output in healthy volunteers.
    Hagenmüller F; Weber C; Hausmann S; Labs R; Malerczyk V; de Looze S; Classen M
    Scand J Gastroenterol; 1987 Jun; 22(5):609-14. PubMed ID: 2888185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisecretory and antiulcer effect of the H2-receptor antagonist famotidine in the rat: comparison with ranitidine.
    Scarpignato C; Tramacere R; Zappia L
    Br J Pharmacol; 1987 Sep; 92(1):153-9. PubMed ID: 2889492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of human gastric secretion by ICI 162,846--a new histamine H2-receptor antagonist.
    Wilson JA; Johnston DA; Penston J; Wormsley KG
    Br J Clin Pharmacol; 1986 Jun; 21(6):685-9. PubMed ID: 2874823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording.
    Savarino V; Mela GS; Zentilin P; Scalabrini P; Bonifacino G; Gambaro P; Celle G
    Digestion; 1989; 42(1):1-6. PubMed ID: 2568299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MK-208, a novel histamine H2-receptor inhibitor with prolonged antisecretory effect.
    McCallum RW; Chremos AN; Kuljian B; Tupy-Visich MA; Huber PB
    Dig Dis Sci; 1985 Dec; 30(12):1139-44. PubMed ID: 2866073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double blind comparison of the effects of cimetidine, ranitidine, famotidine, and placebo on intragastric acidity in 30 normal volunteers.
    Merki HS; Witzel L; Walt RP; Neumann J; Scheurle E; Mappes A; Krammisch H; Heim J; Kaufmann D; Roehmel J
    Gut; 1988 Jan; 29(1):81-4. PubMed ID: 2893761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statistical interpretation of the antisecretory effect of famotidine measured by intragastric pH-metry.
    Hunyady B; Juricskay I; Nagy L; Garamszegi M; Vincze A; Mózsik G
    Eur J Clin Pharmacol; 1996; 50(6):449-56. PubMed ID: 8858270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute effects of ranitidine, famotidine and omeprazole on plasma gastrin in the rat.
    Decktor DL; Pendleton RG; Kellner AT; Davis MA
    J Pharmacol Exp Ther; 1989 Apr; 249(1):1-5. PubMed ID: 2565384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of oral famotidine on 24-hour intragastric acidity.
    Santana IA; Lanzon-Miller S; Pounder RE
    Postgrad Med J; 1986; 62 Suppl 2():39-42. PubMed ID: 2890150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of gastric secretion by a new H2-antagonist, YM-11170 in healthy subjects.
    Miwa M; Tani N; Miwa T
    Int J Clin Pharmacol Ther Toxicol; 1984 Apr; 22(4):214-7. PubMed ID: 6325352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do H2 receptor antagonists have to be given at night? A study of the antisecretory profile of SKF 94482, a new H2 receptor antagonist which has a profound effect on daytime acidity.
    Chiverton SG; Burget DW; Hunt RH
    Gut; 1989 May; 30(5):594-9. PubMed ID: 2567265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-response, meal-stimulated gastric antisecretory study of prostaglandin E1 analog, misoprostol, in man.
    Davis GR; Fordtran JS; Dajani EZ
    Dig Dis Sci; 1988 Mar; 33(3):298-302. PubMed ID: 3125026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans.
    Maczka M; Kwiecień N; Obtułowicz W; Konturek SJ; Kamiński K; Oleksy J; Gabryelewicz A; Torres J
    J Physiol Pharmacol; 1992 Jun; 43(2):139-48. PubMed ID: 1356519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The antisecretory effects of zaltidine, a novel long-acting H2-receptor antagonist, in healthy volunteers and in subjects with a past history of duodenal ulcer.
    Laferla G; Buchanan N; Hearns J; Crean GP; McColl KE; Clucas AT
    Br J Clin Pharmacol; 1986 Oct; 22(4):395-9. PubMed ID: 2876724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH.
    Abe Y; Inamori M; Togawa J; Kikuchi T; Muramatsu K; Chiguchi G; Kawamura H; Kobayashi N; Kirikoshi H; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
    J Gastroenterol; 2004 Jan; 39(1):21-5. PubMed ID: 14767730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of gastric acid suppressants on human gastric motility.
    Parkman HP; Urbain JL; Knight LC; Brown KL; Trate DM; Miller MA; Maurer AH; Fisher RS
    Gut; 1998 Feb; 42(2):243-50. PubMed ID: 9536950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial.
    Feldman M
    JAMA; 1996 May; 275(18):1428-31. PubMed ID: 8618369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.